Development of anti-VEGF therapies for intraocular use: A guide for clinicians

Journal of Ophthalmology

Volumn 2012, Issue , 2012, Pages

  Keane, Pearse A ^a   Sadda, Srinivas R ^b  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84871144937     PISSN: 2090004X     EISSN: 20900058     Source Type: Journal    
DOI: 10.1155/2012/483034     Document Type: Review

References (101)

1. Michaelson I. C., The mode of development of the vascular system of the retina with some observations on its significance for certain retinal disorders. Trans Ophthalmol Soc UK 1948 68 137 180
2. Shweiki D., Itin A., Soffer D., Keshet E., Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992 359 6398 843 845 2-s2.0-0026485002 10.1038/359843a0
3. Aiello L. P., Avery R. L., Arrigg P. G., Keyt B. A., Jampel H. D., Shah S. T., Pasquale L. R., Thieme H., Iwamoto M. A., Park J. E., Nguyen H. V., Aiello L. M., Ferrara N., King G. L., Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. The New England Journal of Medicine 1994 331 22 1480 1487 2-s2.0-0027942607 10.1056/NEJM199412013312203 (Pubitemid 24356306)
4. Adamis A. P., Miller J. W., Bernal M. T., D'Amico D. J., Folkman J., Yeo T. K., Yeo K. T., Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. American Journal of Ophthalmology 1994 118 4 445 450 2-s2.0-0028123090 (Pubitemid 24307211)
5. Kvanta A., Algvere P. V., Berglin L., Seregard S., Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Investigative Ophthalmology and Visual Science 1996 37 9 1929 1934 2-s2.0-0029831672 (Pubitemid 26324159)
6. Lopez P. F., Sippy B. D., Lambert H. M., Thach A. B., Hinton D. R., Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Investigative Ophthalmology and Visual Science 1996 37 5 855 868 2-s2.0-0029879849
7. Carmeliet P., peter.carmeliet@vib-kuleuven.be Jain R. K., jain@steele.mgh.harvard.edu Molecular mechanisms and clinical applications of angiogenesis. Nature 2011 473 7347 298 307 10.1038/nature10144
8. Ferrara N., Kerbel R. S., Angiogenesis as a therapeutic target. Nature 2005 438 7070 967 974 2-s2.0-30744449235 10.1038/nature04483 (Pubitemid 43093963)
9. Carmeliet P., Mechanisms of angiogenesis and arteriogenesis. Nature Medicine 2000 6 4 389 395 2-s2.0-0034076189 10.1038/74651 (Pubitemid 30208155)
10. Ferrara N., Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nature Medicine 2010 16 10 1107 1111 2-s2.0-77957764473 10.1038/nm1010-1107
11. Algire G. H., Chalkley H. W., Legallais F. Y., Park H. D., Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. Journal of the National Cancer Institute 1945 6 73 85
12. Folkman J., Tumor angiogenesis: therapeutic implications. The New England Journal of Medicine 1971 285 21 1182 1186 2-s2.0-0015231516
13. Abraham J. A., Mergia A., Whang J. L., Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. Science 1986 233 4763 545 548 2-s2.0-0022457546 (Pubitemid 16019907)
14. Ferrara N., Henzel W. J., Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochemical and Biophysical Research Communications 1989 161 2 851 858 2-s2.0-0024384470 (Pubitemid 19162712)
15. Leung D. W., Cachianes G., Kuang W. J., Goeddel D. V., Ferrara N., Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989 246 4935 1306 1309 2-s2.0-0024818355 (Pubitemid 20066716)
16. Senger D. R., Galli S. J., Dvorak A. M., Perruzzi C. A., Harvey V. S., Dvorak H. F., Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983 219 4587 983 985 2-s2.0-0021111648
17. Keck P. J., Hauser S. D., Krivi G., Sanzo K., Warren T., Feder J., Connolly D. T., Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989 246 4935 1309 1312 2-s2.0-0024801035 (Pubitemid 20066717)
18. Ferrara N., Damico L., Shams N., Lowman H., Kim R., Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006 26 8 859 870 2-s2.0-33749632278 10.1097/01.iae.0000242842.14624.e7 (Pubitemid 44547437)
19. Miller J. W., Vascular endothelial growth factor and ocular neovascularization. American Journal of Pathology 1997 151 1 13 23 2-s2.0-0030875072 (Pubitemid 27283952)
20. Karkkainen M. J., Mäkinen T., Alitalo K., Lymphatic endothelium: a new frontier of metastasis research. Nature Cell Biology 2002 4 1 E2 E5 2-s2.0-0036144374 10.1038/ncb0102-e2 (Pubitemid 34071967)
21. Dor Y., Porat R., Keshet E., Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. American Journal of Physiology Cell Physiology 2001 280 6 C1367 C1374 2-s2.0-0034979159 (Pubitemid 32553191)
22. Semenza G. L., Signal transduction to hypoxia-inducible factor 1. Biochemical Pharmacology 2002 64 5-6 993 998 2-s2.0-0036710591 10.1016/S0006-2952(02)01168-1 (Pubitemid 35232274)
23. Iliopoulos O., Levy A. P., Jiang C., Kaelin W. G. Jr., Goldberg M. A., Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proceedings of the National Academy of Sciences of the United States of America 1996 93 20 10595 10599 2-s2.0-0029785321 10.1073/pnas.93.20.10595 (Pubitemid 26333032)
24. Ferrara N., Davis-Smyth T., The biology of vascular endothelial growth factor. Endocrine Reviews 1997 18 1 4 25 2-s2.0-0031039243 10.1210/er.18.1.4 (Pubitemid 27076453)
25. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z., Vascular endothelial growth factor (VEGF) and its receptors. FASEB Journal 1999 13 1 9 22 2-s2.0-0032907687 (Pubitemid 29038270)
26. Tischer E., Mitchell R., Hartman T., Silva M., Gospodarowicz D., Fiddes J. C., Abraham J. A., The human gene for vascular endothelial growth factor: multiple protein forms are encoded through alternative exon splicing. Journal of Biological Chemistry 1991 266 18 11947 11954 2-s2.0-0025999033
27. Ferrara N., Gerber H. P., LeCouter J., The biology of VEGF and its receptors. Nature Medicine 2003 9 6 669 676 2-s2.0-0037699954 10.1038/nm0603-669 (Pubitemid 36749215)
28. Keyt B. A., Nguyen H. V., Berleau L. T., Duarte C. M., Park J., Chen H., Ferrara N., Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors: generation of receptor-selective VEGF variants by site-directed mutagenesis. Journal of Biological Chemistry 1996 271 10 5638 5646 2-s2.0-0029920944
29. de Vries C., Escobedo J. A., Ueno H., Houck K., Ferrara N., Williams L. T., The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992 255 5047 989 991 2-s2.0-0026572345
30. Soker S., Takashima S., Miao H. Q., Neufeld G., Klagsbrun M., Neuropilin-1 is expressed by endothelial and tumor cells as an isoform- specific receptor for vascular endothelial growth factor. Cell 1998 92 6 735 745 2-s2.0-0032549799 10.1016/S0092-8674(00)81402-6 (Pubitemid 28155313)
31. Plouet J., Schilling J., Gospodarowicz D., Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO Journal 1989 8 12 3801 3806 2-s2.0-0024816246 (Pubitemid 20016061)
32. Gerber H. P., Hillan K. J., Ryan A. M., Kowalski J., Keller G. A., Rangell L., Wright B. D., Radtke F., Aguet M., Ferrara N., VEGF is required for growth and survival in neonatal mice. Development 1999 126 6 1149 1159 2-s2.0-0032931234 (Pubitemid 29182112)
33. Yuan F., Chen Y., Dellian M., Safabakhsh N., Ferrara N., Jain R. K., Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proceedings of the National Academy of Sciences of the United States of America 1996 93 25 14765 14770 2-s2.0-0029949160 10.1073/pnas.93.25.14765 (Pubitemid 26419043)
34. Benjamin L. E., Golijanin D., Itin A., Pode D., Keshet E., Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. Journal of Clinical Investigation 1999 103 2 159 165 2-s2.0-0032952010 (Pubitemid 29053133)
35. Clauss M., Gerlach M., Gerlach H., Brett J., Wang F., Familletti P. C., Pan Y. C. E., Olander J. V., Connolly D. T., Stern D., Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. Journal of Experimental Medicine 1990 172 6 1535 1545 2-s2.0-0025688912 10.1084/jem.172.6.1535
36. Miyamoto K., Khosrof S., Bursell S. E., Moromizato Y., Aiello L. P., Ogura Y., Adamis A. P., Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). American Journal of Pathology 2000 156 5 1733 1739 2-s2.0-0033838925 (Pubitemid 30646710)
37. Lamoreaux W. J., Fitzgerald M. E. C., Reiner A., Hasty K. A., Charles S. T., Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvascular Research 1998 55 1 29 42 2-s2.0-0031870786 10.1006/mvre.1997.2056 (Pubitemid 28368411)
38. Roberts W. G., Palade G. E., Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. Journal of Cell Science 1995 108, part 6 2369 2379 2-s2.0-0029010434
39. Ku D. D., Zaleski J. K., Liu S., Brock T. A., Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. American Journal of Physiology Heart and Circulatory Physiology 1993 265 2 H586 H592 2-s2.0-0027217832 (Pubitemid 23273595)
40. Nishijima K., Ng Y. S., Zhong L., Bradley J., Schubert W., Jo N., Akita J., Samuelsson S. J., Robinson G. S., Adamis A. P., Shima D. T., Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. American Journal of Pathology 2007 171 1 53 67 2-s2.0-34547702738 10.2353/ajpath.2007.061237 (Pubitemid 47339226)
41. Aiello L. P., Pierce E. A., Foley E. D., Takagi H., Chen H., Riddle L., Ferrara N., King G. L., Smith L. E. H., Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proceedings of the National Academy of Sciences of the United States of America 1995 92 23 10457 10461 2-s2.0-0028786651 10.1073/pnas.92.23.10457
42. Adamis A. P., Shima D. T., Tolentino M. J., Gragoudas E. S., Ferrara N., Folkman J., D'Amore P. A., Miller J. W., Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Archives of Ophthalmology 1996 114 1 66 71 2-s2.0-0030067257 (Pubitemid 26026196)
43. Tolentino M. J., Miller J. W., Gragoudas E. S., Chatzistefanou K., Ferrara N., Adamis A. P., Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Archives of Ophthalmology 1996 114 8 964 970 2-s2.0-0029739620 (Pubitemid 26271462)
44. Ng E. W. M., Shima D. T., Calias P., Cunningham E. T. Jr., Guyer D. R., Adamis A. P., Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nature Reviews Drug Discovery 2006 5 2 123 132 2-s2.0-33645095226 10.1038/nrd1955
45. Keefe A. D., Pai S., Ellington A., Aptamers as therapeutics. Nature Reviews Drug Discovery 2010 9 7 537 550 2-s2.0-77954220072 10.1038/nrd3141
46. Eaton B. E., The joys of in vitro selection: chemically dressing oligonucleotides to satiate protein targets. Current Opinion in Chemical Biology 1997 1 1 10 16 2-s2.0-0031151974 (Pubitemid 127435140)
47. Ruckman J., Green L. S., Beeson J., Waugh S., Gillette W. L., Henninger D. D., Claesson-Welsh L., Janjić N., 2'-fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165): inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. Journal of Biological Chemistry 1998 273 32 20556 20567 2-s2.0-0032493654 10.1074/jbc.273.32.20556 (Pubitemid 28377626)
48. Ishida S., Usui T., Yamashiro K., Kaji Y., Amano S., Ogura Y., Hida T., Oguchi Y., Ambati J., Miller J. W., Gragoudas E. S., Ng Y. S., D'Amore P. A., Shima D. T., Adamis A. P., VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. Journal of Experimental Medicine 2003 198 3 483 489 2-s2.0-0043125643 10.1084/jem.20022027 (Pubitemid 36976059)
49. Martin D. F., Klein M., Haller J., Adamis A., Gragoudas E., Miller J., Blumenkrantz M., Goldberg M., Yannuzzi L., Henninger D., Wiegand L. B., Chen L. S., Drolet D. W., Gill S. C., Bill J., Tomkinson B., Bendele R. A., O'Shaughnessy D., Guyer D. R., Patel S., Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002 22 2 143 152 2-s2.0-0036959644 10.1097/00006982-200204000-00002 (Pubitemid 36125089)
50. Lee S., Jilan S. M., Nikolova G. V., Carpizo D., Iruela-Arispe M. L., Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. Journal of Cell Biology 2005 169 4 681 691 2-s2.0-22344437713 10.1083/jcb.200409115 (Pubitemid 41002860)
51. Park J. E., Keller G. A., Ferrara N., The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Molecular Biology of the Cell 1993 4 12 1317 1326 2-s2.0-0027751890 (Pubitemid 24045761)
52. Tucker C. E., Chen L. S., Judkins M. B., Farmer J. A., Gill S. C., Drolet D. W., Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. Journal of Chromatography B 1999 732 1 203 212 2-s2.0-0032876515 10.1016/S0378-4347(99) 00285-6 (Pubitemid 29421761)
53. Drolet D. W., Nelson J., Tucker C. E., Zack P. M., Nixon K., Bolin R., Judkins M. B., Farmer J. A., Wolf J. L., Gill S. C., Bendele R. A., Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharmaceutical Research 2000 17 12 1503 1510 2-s2.0-0034466813 10.1023/A:1007657109012 (Pubitemid 32217559)
54. Apte R. S., Modi M., Masonson H., Patel M., Whitfield L., Adamis A. P., Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology 2007 114 9 1702 1712
55. Gragoudas E. S., Adamis A. P., Cunningham E. T. Jr., Pegaptanib for neovascular age-related macular degeneration. The New England Journal of Medicine 2004 351 27 2805 2816 2-s2.0-11144239923 10.1056/NEJMoa042760 (Pubitemid 40051904)
56. Singerman L. J., Masonson H., Patel M., Adamis A. P., Buggage R., Cunningham E., Goldbaum M., Katz B., Guyer D., Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF inhibition study in ocular neovascularisation (VISION) trial. British Journal of Ophthalmology 2008 92 12 1606 1611 2-s2.0-57149091202 10.1136/bjo.2007.132597
57. Sultan M. B., marla.b.sultan@pfizer.com Zhou D., Loftus J., Dombi T., Ice K. S., A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 2011 118 6 1107 1118 10.1016/j.ophtha.2011.02.045
58. Meyer C. H., meyereye@yahoo.com Holz F. G., Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye 2011 25 6 661 672 10.1038/eye.2011.66
59. Gordon M. S., Cunningham D., Managing patients treated with bevacizumab combination therapy. Oncology 2005 69 supplement 3 25 33 2-s2.0-27944456516 10.1159/000088481 (Pubitemid 41680950)
60. Tufail A., Patel P. J., Egan C., Hykin P., da Cruz L., Gregor Z., Dowler J., Majid M. A., Bailey C., Mohamed Q., Johnston R., Bunce C., Xing W., ABC Trial Investigators, Bevacizumab for neovascular age related macular degeneration (ABC trial): multicentre randomised double masked study. BMJ 2010 340 c2459 2-s2.0-77954470039 10.1136/bmj.c2459
61. Martin D. F., Maguire M. G., maguirem@mail.med.upenn.edu Ying G. S., Grunwald J. E., Fine S. L., Jaffe G. J., Ranibizumab and bevacizumab for neovascular age-related macular degeneration. The New England Journal of Medicine 2011 364 20 1897 1908 10.1056/NEJMoa1102673
62. Kim K. J., Li B., Houck K., Winer J., Ferrara N., The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992 7 1 53 64 2-s2.0-0026708632
63. Presta L. G., Chen H., O'Connor S. J., Chisholm V., Meng Y. G., Krummen L., Winkler M., Ferrara N., Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Research 1997 57 20 4593 4599 2-s2.0-0030856731 (Pubitemid 27441066)
64. Peters S., Julien S., Heiduschka P., Grisanti S., Ziemssen F., Adler M., Schraermeyer U., Bartz-Schmidt K. U., Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. British Journal of Ophthalmology 2007 91 6 827 831 2-s2.0-34249777252 10.1136/bjo.2006.109702 (Pubitemid 46846661)
65. Brar V. S., Sharma R. K., Murthy R. K., Chalam K. V., Evaluation of differential toxicity of varying doses of bevacizumab on retinal ganglion cells, retinal pigment epithelial cells, and vascular endothelial growth factor-enriched choroidal endothelial cells. Journal of Ocular Pharmacology and Therapeutics 2009 25 6 507 511 2-s2.0-77149166301 10.1089/jop.2009.0028
66. Han Y. S., Lee J. E., Jung J. W., Lee J. S., Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization. Graefe's Archive for Clinical and Experimental Ophthalmology 2009 247 4 541 548 2-s2.0-62149145802 10.1007/s00417-008-0976-3
67. Tatar O., Yoeruek E., Szurman P., Bartz-Schmidt K. U., Adam A., Shinoda K., Eckardt C., Boeyden V., Claes C., Pertile G., Scharioth G. B., Grisanti S., Effect of bevacizumab on inflammation and proliferation in human choroidal neovascularization. Archives of Ophthalmology 2008 126 6 782 790 2-s2.0-45149087968 10.1001/archopht.126.6.782 (Pubitemid 351831327)
68. Liu L., Ammar D. A., Ross L. A., Mandava N., Kahook M. Y., Carpenter J. F., john.carpenter@ucdenver.edu Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Investigative Ophthalmology and Visual Science 2011 52 2 1023 1034 10.1167/iovs.10-6431
69. Bakri S. J., Snyder M. R., Reid J. M., Pulido J. S., Ezzat M. K., Singh R. J., Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007 114 12 2179 2182 2-s2.0-36549039554 10.1016/j.ophtha.2007.09.012 (Pubitemid 350181137)
70. Bakri S. J., Snyder M. R., Reid J. M., Pulido J. S., Singh R. J., Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007 114 5 855 859 2-s2.0-34247400587 10.1016/j.ophtha.2007.01.017 (Pubitemid 46635858)
71. Meyer C. H., meyereye@yahoo.com Krohne T. U., Holz F. G., Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina 2011 31 9 1877 1884 10.1097/IAE. 0b013e318217373c
72. Shahar J., Avery R. L., Heilweil G., Barak A., Zemel E., Lewis G. P., Johnson P. T., Fisher S. K., Perlman I., Loewenstein A., Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006 26 3 262 269 2-s2.0-33646464758 10.1097/00006982- 200603000-00002 (Pubitemid 44318177)
73. Patel P. J., Bunce C., Tufail A., Bunce C., da Cruz L., Dowler J., Egan C., Gregor Z., Hykin P., Mohamed Q., Johnston R., Majid M., Bailey C., Ikeji F., Richardson M., Waller K., A randomised, double-masked phase III/IV study of the efficacy and safety of Avastin (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration: clinical trial design. Trials 2008 9 56 2-s2.0-55649114212 10.1186/1745-6215-9-56
74. Mordenti J., Cuthbertson R. A., Ferrara N., Thomsen K., Berleau L., Licko V., Allen P. C., Valverde C. R., Meng Y. G., Fei D. T. W., Fourre K. M., Ryan A. M., anne-ryan@groton.pfizer.com Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicologic Pathology 1999 27 5 536 544 (Pubitemid 29446822)
75. Chen Y., Wiesmann C., Fuh G., Li B., Christinger H. W., McKay P., de Vos A. M., Lowman H. B., Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. Journal of Molecular Biology 1999 293 4 865 881 2-s2.0-0033527584 10.1006/jmbi.1999.3192 (Pubitemid 29527672)
76. Krzystolik M. G., Afshari M. A., Adamis A. P., Gaudreault J., Gragoudas E. S., Michaud N. A., Li W., Connolly E., O'Neill C. A., Miller J. W., Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Archives of Ophthalmology 2002 120 3 338 346 2-s2.0-0036129304 (Pubitemid 34250056)
77. Gaudreault J., Fei D., Beyer J. C., Ryan A., Rangell L., Shiu V., Damico L. A., Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 2007 27 9 1260 1266 2-s2.0-36749003833 10.1097/IAE. 0b013e318134eecd (Pubitemid 350211535)
78. Gaudreault J., Fei D., Rusit J., Suboc P., Shiu V., Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Investigative Ophthalmology and Visual Science 2005 46 2 726 733 2-s2.0-13944266313 10.1167/iovs.04-0601 (Pubitemid 40270359)
79. Brown D. M., Kaiser P. K., Michels M., Soubrane G., Heier J. S., Kim R. Y., Sy J. P., Schneider S., Ranibizumab versus verteporfin for neovascular age-related macular degeneration. The New England Journal of Medicine 2006 355 14 1432 1444 2-s2.0-33749451356 10.1056/NEJMoa062655 (Pubitemid 44511558)
80. Rosenfeld P. J., Brown D. M., Heier J. S., Boyer D. S., Kaiser P. K., Chung C. Y., Kim R. Y., Ranibizumab for neovascular age-related macular degeneration. The New England Journal of Medicine 2006 355 14 1419 1431 2-s2.0-33749445317 10.1056/NEJMoa054481 (Pubitemid 44511557)
81. Singer M., Wong P., Wang P.-W., Scott L., HORIZON extension trial of ranibizumab (LUCENTIS(R)) for neovascular age-related macular degeneration (AMD): two-year safety and efficacy results. Investigative Ophthalmology & Visual Science 2009 50 3093
82. Mitchell P., Korobelnik J.-F., Lanzetta P., Holz F. G., Prünte C., Schmidt-Erfurth U., Tano Y., Wolf S., Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. British Journal of Ophthalmology 2010 94 1 2 13 2-s2.0-74549137478 10.1136/bjo.2009.159160
83. Boyer D. S., Heier J. S., Brown D. M., Francom S. F., Ianchulev T., Rubio R. G., A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009 116 9 1731 1739 2-s2.0-69249222585 10.1016/j.ophtha.2009.05.024
84. Ueta T., Yanagi Y., Tamaki Y., Yamaguchi T., Cerebrovascular accidents in ranibizumab. Ophthalmology 2009 116 2 362 2-s2.0-58849084256 10.1016/j.ophtha.2008.09.046
85. Elman M. J., Aiello L. P., Beck R. W., Bressler N. M., Bressler S. B., Edwards A. R., Ferris F. L., Friedman S. M., Glassman A. R., Miller K. M., Scott I. U., Stockdale C. R., Sun J. K., Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010 117 6 1064 1077 e1035 2-s2.0-77952779304 10.1016/j.ophtha.2010.02.031
86. Mitchell P., paul.mitchell@sydney.edu.au Bandello F., Schmidt-Erfurth U., Lang G. E., Massin P., Schlingemann R. O., Sutter F., Simader C., Burian G., Gerstner O., Weichselberger A., The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011 118 4 615 625 10.1016/j.ophtha.2011.01.031
87. Brown D. M., Campochiaro P. A., Singh R. P., Li Z., Gray S., Saroj N., Rundle A. C., Rubio R. G., Murahashi W. Y., Ranibizumab for macular edema following central retinal vein occlusion. Six-month primary end point results of a phase III study. Ophthalmology 2010 117 6 1124 1133 e1121 2-s2.0-77952889477 10.1016/j.ophtha.2010.02.022
88. Campochiaro P. A., pcampo@jhmi.edu Brown D. M., Awh C. C., Lee S. Y., Gray S., Saroj N., Murahashi W. Y., Rubio R. G., Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011 118 10 2041 2049 10.1016/j.ophtha.2011.02.038
89. Campochiaro P. A., Heier J. S., Feiner L., Gray S., Saroj N., Rundle A. C., Murahashi W. Y., Rubio R. G., Ranibizumab for macular edema following branch retinal vein occlusion. Six-month primary end point results of a phase III study. Ophthalmology 2010 117 6 1102 1112 e1101 2-s2.0-77952891051 10.1016/j.ophtha.2010.02.021
90. Brown D. M., dmbmd@houstonretina.com Campochiaro P. A., Bhisitkul R. B., Ho A. C., Gray S., Saroj N., Adamis A. P., Rubio R. G., Murahashi W. Y., Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011 118 8 1594 1602 10.1016/j.ophtha.2011.02.022
91. Dixon J. A., Oliver S. C. N., Olson J. L., Mandava N., VEGF trap-eye for the treatment of neovascular age-related macular degeneration. Expert Opinion on Investigational Drugs 2009 18 10 1573 1580 2-s2.0-70349330817 10.1517/13543780903201684
92. Holash J., Davis S., Papadopoulos N., Croll S. D., Ho L., Russell M., Boland P., Leidich R., Hylton D., Burova E., Ioffe E., Huang T., Radziejewski C., Bailey K., Fandl J. P., Daly T., Wiegand S. J., Yancopoulos G. D., Rudge J. S., VEGF-trap: a VEGF blocker with potent antitumor effects. Proceedings of the National Academy of Sciences of the United States of America 2002 99 17 11393 11398 2-s2.0-0037143764 10.1073/pnas.172398299 (Pubitemid 34920936)
93. Kaiser P. K., Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. American Journal of Ophthalmology 2006 142 4 660 668 2-s2.0-33748979577 10.1016/j.ajo.2006.05.061 (Pubitemid 44442083)
94. Nork T. M., tmnork@wisc.edu Dubielzig R. R., Christian B. J., Miller P. E., Miller J. M., Cao J., Zimmer E. P., Wiegand S. J., Prevention of experimental choroidal neovascularization and resolution of active lesions by VEGF trap in nonhuman primates. Archives of Ophthalmology 2011 129 8 1042 1052 10.1001/archophthalmol.2011.210
95. Saishin Y., Saishin Y., Takahashi K., Silva R. L. E., Hylton D., Rudge J. S., Wiegand S. J., Campochiaro P. A., VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. Journal of Cellular Physiology 2003 195 2 241 248 2-s2.0-0037401890 10.1002/jcp.10246 (Pubitemid 36384298)
96. Cao J., Zhao L., Li Y., Liu Y., Xiao W., Song Y., Luo L., Huang D., Yancopoulos G. D., Wiegand S. J., Wen R., rwen@med.miami.edu A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated Inflammation and fibrosis by VEGF Trap. Investigative Ophthalmology and Visual Science 2010 51 11 6009 6017 10.1167/iovs.09-4956
97. Bressler N. M., Antiangiogenic approaches to age-related macular degeneration today. Ophthalmology 2009 116 10 S15 S23 2-s2.0-70349469696 10.1016/j.ophtha.2009.06.048
98. Kaiser P. K., Symons R. C. A., Shah S. M., Quinlan E. J., Tabandeh H., Do D. V., Reisen G., Lockridge J. A., Short B., Guerciolini R., Nguyen Q. D., RNAi-based treatment for neovascular age-related macular degeneration by sirna-027. American Journal of Ophthalmology 2010 150 1 33 39 e32 2-s2.0-77953909544 10.1016/j.ajo.2010.02.006
99. Kaiser P. K., Combination therapy with verteporfin and anti-VEGF agents in neovascular age-related macular degeneration: where do we stand? British Journal of Ophthalmology 2010 94 2 143 145 2-s2.0-76149137247 10.1136/bjo.2009.159863
100. Spaide R. F., Perspectives: rationale for combination therapies for choroidal neovascularization. American Journal of Ophthalmology 2006 141 1 149 156 2-s2.0-29544436881 10.1016/j.ajo.2005.07.025 (Pubitemid 43016187)
101. Zarbin M. A., Rosenfeld P. J., Pathway-based therapies for age-related macular degeneration: an integrated survey of emerging treatment alternatives. Retina 2010 30 9 1350 1367 2-s2.0-77958524704 10.1097/IAE.0b013e3181f57e30